Overview
Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19
Status:
Active, not recruiting
Active, not recruiting
Trial end date:
2021-12-31
2021-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study will compare two drugs (hydroxychloroquine and azithromycin) to see if hydroxychloroquine is better than azithromycin in treating hospitalized patients with suspected or confirmed COVID-19.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Intermountain Health Care, Inc.Collaborator:
University of UtahTreatments:
Azithromycin
Hydroxychloroquine
Criteria
Inclusion Criteria:- Adult (age ≥ 18 years)
- Confirmed OR suspected COVID-19,
- Confirmed: Positive assay for COVID-19 within the last 10 days
- Suspected: Pending assay for COVID-19 WITH high clinical suspicion
- Scheduled for admission or already admitted to an inpatient bed
Exclusion Criteria:
- Allergy to hydroxychloroquine or azithromycin
- History of bone marrow transplant
- Known G6PD deficiency
- Chronic hemodialysis or Glomerular Filtration Rate < 20ml/min
- Psoriasis
- Porphyria
- Concomitant use of digitalis, flecainide, amiodarone, procainamide, propafenone,
cimetidine, dofetilide, phenobarbital, phenytoin, or sotalol
- Known history of long QT syndrome
- Current known QTc>500 msec
- Pregnant or nursing
- Prisoner
- Weight < 35kg
- Seizure disorder
- Severe liver disease
- Outpatient use of hydroxychloroquine for treatment of a disease other than COVID-19 OR
has received more than 2 days of hydroxychloroquine or azithromycin for suspected or
confirmed COVID-19
- Patient has recovered from COVID-19 and/or is being discharged from the hospital on
day of enrollment.
- Treating physician refuses to allow patient participation in the study
- Unable to obtain informed consent
- Prior enrollment in this study